Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696092 | 1.00 | ALDH1A1 (0.39) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL14511230 | 1.00 | ALDH1A1 (0.39) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL1098026 | 0.96 | ALDH1A1 (0.36) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL14511226 | 0.96 | ALDH1A1 (0.36) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL1098024 | 0.96 | ALDH1A1 (0.36) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL5846892 | 0.94 | ALDH1A1 (0.36) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL5846888 | 0.94 | ALDH1A1 (0.36) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL1097346 | 0.90 | BCHE (0.39) | ALDH1A1GSTP1BCHEMETAP2 | |
| SCHEMBL1096195 | 0.90 | BCHE (0.39) | ALDH1A1GSTP1BCHEMETAP2 | |
| SCHEMBL1096197 | 0.90 | BCHE (0.39) | ALDH1A1GSTP1BCHEMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072862-A9 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025072862-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-04-03 | — | — | WO | disclosed |
| EP-1163250-B1 | IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES | EXIQON AS (DK) | 2006-07-12 | — | — | EP | disclosed |
| US-6734291-B2 | SULFONYLATION OF A DI(HYDROXYMETHANE)FURO(2,3-D)1,3-DIOXOLE DERIVATIVE WITH A SULFONYL HALIDE | EXIQON A/S (DK) | 2004-05-11 | — | — | US | disclosed |
| US-6639059-B1 | Novel synthesis strategy comprising novel key intermediate, (2.2.1)bicyclo nucleosides are produced at least two steps shorter than any previously known strategy; 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-alpha-D-ribofuranose | EXIQON A/S (DK) | 2003-10-28 | — | — | US | disclosed |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | EXIQON A/S | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | NSUN2, RNGTT, RNMT | ALDH1A1 617/4885GSTP1 2646/4885LMNA 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.